Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03642132 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 22, 2018
Last Update Posted : June 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Cancer | Drug: Chemotherapy + avelumab followed by avelumab + talazoparib Drug: Chemotherapy followed by talazoparib maintenance Drug: Chemotherapy + bevacizumab followed by bevacizumab | Phase 3 |
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, international, multi-center, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). The primary endpoint is progression-free survival (PFS) as determined based on blinded independent central review (BICR) assessment per RECIST v1.1.
On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study. The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial's initiation, including the previously announced interim results from JAVELIN Ovarian 100 study (B9991010), which was stopped due to futility of efficacy at a planned interim analysis on 21 December 2018. The alliance determined that the degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasizes the need to better understand the role of immunotherapy in ovarian cancer. Additional factors include the rapidly changing treatment landscape and the approval of a PARP inhibitor in the frontline maintenance setting. The decision to discontinue the JAVELIN Ovarian PARP 100 trial was not made for safety reasons.
Patients who remain in the study will continue receiving investigational products according to their randomized treatment assignment and will be monitored for appropriate safety assessments until treatment discontinuation.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 79 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100) |
| Actual Study Start Date : | July 19, 2018 |
| Estimated Primary Completion Date : | November 28, 2021 |
| Estimated Study Completion Date : | November 28, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: chemotherapy, avelumab and talazoparib
Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
|
Drug: Chemotherapy + avelumab followed by avelumab + talazoparib
Chemotherapy Period Paclitaxel Carboplatin Avelumab Maintenance Period Avelumab Talazoparib |
|
Experimental: chemotherapy, and talazoparib
Platinum-based chemotherapy followed by talazoparib maintenance
|
Drug: Chemotherapy followed by talazoparib maintenance
Chemotherapy Period Paclitaxel Carboplatin Maintenance Period Talazoparib |
|
Active Comparator: chemotherapy and bevacizumab
Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
|
Drug: Chemotherapy + bevacizumab followed by bevacizumab
Chemotherapy Period Paclitaxel Carboplatin Bevacizumab Maintenance Period Bevacizumab |
- Progression-Free Survival (PFS) - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Baseline to measured progressive disease (up to approximately 41 months) ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) The time from the date of randomization to the date of the first documentation of Progression of Disease or death due to any cause, whichever occurs first. Assessments to be completed by third-party blinded independent committee review.
- Overall Survival (OS) - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Baseline to date of death from any cause (up to approximately 93 months) ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) Overall survival (OS) is time from the date of randomization to the date of death due to any cause.
- Euro Quality of Life (EQ-5D-5L) - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Every 3 weeks during chemotherapy period (up to 18 weeks), and every 6 weeks (up to 24 months) during maintenance and follow-up period (up to 3 years). ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Health State Profile which has individualsrate their level of problems (none, slight, moderate, severe, or extreme/unable) in 5 areas (mobility, self care, usual activities, pain/discomfort, and anxiety/depression).
- NFOSI-18 - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Day 1, 8, 15 of cycles 1,2,3 and D1 of cycles 4, 5, 6 in chemotherpy period (cycle is 21 days) and every 6 weeks (up to 24 months) during maintenance and follow-up period (up to 3 years). ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) NFOSI-18 is an ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. DRS-P subscale include 9 physical symptoms/concerns (energy, pain, ill, stomach cramps, fatigue, constipation, stomach swelling, bowel control and sleep) and the disease related symptoms-emotional subscale include 1 emotional symptom/concern (worry condition will get worse). The treatment side effect subscale includes 5 items (nausea, hair loss, bothered by side effects, vomiting and skin problems). The functional well-being subscale includes 3 items (able to get around, enjoy life, and content with QoL).
- ADA (Anti-Drug Antibodies) against Avelumab - (Obsolete) [ Time Frame: Every 3 weeks during 1st 4 cycles of chemotherapy ( cycle 21 days), day 1 and 29 during 1st cycle of maintenance (cycle 42 days) and every 12 weeks (up to 60 weeks). ]
The original study objectives/endpoints are no longer applicable and/or feasible.
(Obsolete) The percentage of participants with positive ADA and neutralizing antibodies will be summarized in treatment Arm A. All samples that are positive for ADA will also undergo characterization for Neutralizing Antibodies (NAb).
- Progression Free Survival after the second line of therapy (PFS2) - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Baseline up to second progression up to approximately 41 months. ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) Time from the date of randomization to the start of second subsequent treatment after first PD by Investigator assessment, or death from any cause, whichever occurs first.
- Cmax - Talazoparib - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Pre-dose on Days 1, 15, and 29 of Cycle 1 (Cycle is 42 days) of maintenance treatment. ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) Maximum Observed Plasma Concentration (Cmax)
- Cmax - Avelumab - (Obsolete after effectiveness of protocol amendment 2) [ Time Frame: Every 3 weeks during 1st 4 cycles of chemotherapy ( cycle 21 days), day 1 and 29 during 1st cycle of maintenance (cycle 42 days) and every 12 weeks (up to 60 weeks). ]
The original study objectives/endpoints are no longer applicable and/or feasible after effectiveness of protocol amendment 2.
(Obsolete) Maximum Observed Plasma Concentration (Cmax).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed Stage III IV epithelial ovarian, fallopian tube, or primary peritoneal cancer including carcinosarcoma with high-grade serous component.
- Patients must be candidates for bevacizumab in combination with platinum based chemotherapy and previously untreated.
-
Must have completed a primary surgical debulking procedure, or be candidates for neoadjuvant chemotherapy with planned interval debulking surgery.
- Patients who completed primary debulking must have had incompletely resected disease that is macroscopically/grossly visible and at least with lesions >1 mm and be randomized at a maximum of 8 weeks after surgery.
-
For patients who are candidates for neoadjuvant chemotherapy, the diagnoses must have been confirmed by:
- Core tissue (not fine-needle aspiration) biopsy is required for diagnosis.
- Stage IIIC-IV documented via imaging or surgery (without attempt at cytoreduction).
- Serum CA-125/CEA ratio >25. If the serum CA-125/CEA ratio is <25, then workup should be negative for the presence of a primary gastrointestinal or breast malignancy (<6 weeks before start of neoadjuvant treatment).
- Randomization must occur within 8 weeks after diagnosis.
- Availability of an archival FFPE tumor tissue block or a minimum of 25 slides, together with an accompanying original H&E slide. If archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample must be obtained in accordance with local institutional practice for tumor biopsies. Tumor tissue must contain 40% or greater tumor nuclei per central laboratory assessment.
- ECOG performance status 0-1
- Age >=18 years (or >=20 years in Japan).
- Adequate bone marrow, hepatic, and renal function and blood coagulation
Exclusion Criteria:
- Non-epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors.
- Patients for whom intraperitoneal cytotoxic chemotherapy is planned.
- Prior exposure to immunotherapy with interleukin (IL)-2, interferon alpha (IFN-α), or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen 4 (anti-CTLA4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, excluding therapeutic anticancer vaccines.
- Prior treatment with a PARP inhibitor.
- Prior treatment with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumab.
- Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any reason within 4 weeks prior to randomization and/or incomplete recovery from surgery.
- Prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
- Prior targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their ovarian, peritoneal primary or fallopian tube carcinoma.
- Prior organ transplantation including allogenic stem cell transplantation.
- Diagnosis of Myelodysplastic Syndrome (MDS).
- Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03642132
Show 73 study locations
| Study Chair: | Bradley Monk, MD | Department of Obstetrics and Gynecology, University of Arizona College of Medicine - Phoenix | |
| Study Chair: | Jonathan Ledermann, MD | UCL Cancer Institute at University College London | |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT03642132 |
| Other Study ID Numbers: |
B9991030 2017-004456-30 ( EudraCT Number ) B9991030 ( Other Identifier: Alias Study Number ) JAVELIN OVARIAN PARP 100 ( Other Identifier: Alias Study Number ) |
| First Posted: | August 22, 2018 Key Record Dates |
| Last Update Posted: | June 9, 2021 |
| Last Verified: | June 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
| URL: | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
untreated epithelial ovarian cancer fallopian tube carncer primary peritoneal cancer |
|
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Bevacizumab Talazoparib Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |